Infectious disease

Stop TB Partnership

Established in 1998 and hosted by the World Health Organization (WHO), the Stop TB Partnership aims to provide global leadership, strategy, and coordinating mechanisms. The Stop TB priorities are to expand, adapt, and improve strategies to control and eliminate TB in support of the World Health Assembly Targets set by 2005 (70% case-detection and 85% cure-rates) and the Millennium Development Goals. The mission is to ensure that every TB patient has access to TB treatment and cure, to protect vulnerable populations from TB and to reduce the social and economic toll that TB exerts on families, communities and nations.

Pneumococcal Conjugate Vaccine Programs

Pneumococcal disease takes the lives of 1.6 million people each year, including approximately 800,000 children before their fifth birthday. More than 90% of these deaths occur in developing countries. Its most common serious form, pneumonia, accounts for one in every four child deaths. GlaxoSmithKline and Pfizer have developed pneumococcal conjugate vaccines which protect against this major health threat.

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Pfizer - PDA Positive Partnership

Since 2004, Pfizer Foundation New York, Pfizer Thailand Foundation and the Population and Community Development Association (PDA) have collaborated to improve the quality of life of people living with HIV/AIDS. This micro-credit loan scheme provides economic security for people living with AIDS while reducing stigmatization and discrimination in their communities. Since 2007, the Pfizer Thailand Foundation has provided financial support for the program and has worked together with PDA to equip project members with technical skills.

Pfizer - Mobilize Against Malaria

Unveiled at the Clinton Global Initiative in 2006, Mobilize Against Malaria is Pfizer's signature social investment in malaria, supporting programs to reduce the malaria burden in three hard-hit African countries, Ghana, Kenya and Senegal, over a five year period (2007-2011). Under this USD 15 million program, Pfizer helps four leading NGOs to close critical gaps in malaria treatment, training, and public demand for quality services. In Ghana, Pfizer is helping to bring the public and private sectors together to find new solutions to the malaria challenge.

Pfizer - Infectious Diseases Institute

The Infectious Diseases Institute (IDI) in Kampala, Uganda was established in 2004 as a Center of Excellence in Infectious Disease, combining a research program, innovative training program, and locally relevant strategies for prevention, treatment & care, to build regional capacity to address HIV/AIDS, malaria and tuberculosis. Partners in the IDI include Accordia Global Health Foundation, Makerere University and Mulago Hospital, the Ugandan Ministry of Health, and the Infectious Diseases Society of America.

Pfizer - Azithromycin/chloroquine for Malaria

Pfizer, in partnership with Medicines for Malaria Venture (MMV) and London School of Hygiene and Tropical Medicine, is developing a fixed dose combination of azithromycin and chloroquine (AZCQ) for intermittent treatment of malaria in pregnant women (IPTp) in sub-Saharan Africa. IPTp is aimed at lowering the incidence of adverse pregnancy outcomes associated with malaria in pregnancy. Sulfadoxine/pyrimethamine (SP) is the current standard of care for IPTp in high transmission areas in Africa.

PEPFAR Partnership for Pediatric AIDS Treatment

The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Partnership for Pediatric AIDS Treatment was launched in 2006. This public-private partnership includes innovator and generic pharmaceutical companies and multilateral organizations such as UNAIDS, WHO and UNICEF.

Pediatric Formulations for ARVs

Of the 2.5 million HIV-positive children in the world in 2007, nearly 90 per cent were in sub-Saharan Africa, according to UNAIDS.

Pediatric Dengue Vaccine Initiative (PDVI)

Dengue fever is the second most widespread tropical disease after malaria. The Pediatric Dengue Vaccine Initiative (PDVI), a Bill and Melinda Gates funded initiative of the International Vaccine Institute, in Seoul, Korea, was established in 2001 to accelerate the development of a dengue vaccine that is appropriate, safe and accessible to poor children in endemic countries.

Pages